Breast Cancer Drugs: World Market Prospects 2010-2025
How will expanding patient populations, improved diagnosis and new treatments benefit this market?
The breast cancer treatments market generated pharmaceutical revenues of over $11bn worldwide in 2009. The incidence and prevalence of breast cancer have been rising worldwide, in line with ageing populations, lifestyle/environmental factors and improvements in diagnosis. Expanding patient populations worldwide offer significant commercial and therapeutic opportunities, which our new report forecasts and discusses. Governments and other healthcare providers are investing in health education, diagnosis and treatments for this serious - but controllable - disorder.
As Breast Cancer Drugs: World Market Prospects 2010-2025 shows, breast cancer treatment is prominent in the healthcare sector. Which segments of the breast cancer market will grow fastest in years to come? How will the industry cope with patent expiry? What are the therapeutic and commercial trends to watch? How will national markets perform from 2010 to 2025? What will happen to the current leading products and drug classes? Our new report covers those and other questions, providing the information that you need.
We predict that the global market for breast cancer drugs will expand from 2010 onwards, driven by significant prevalence of the disease in developed and developing countries. National markets for those products will expand at different rates, as will different treatment forms. The market will depend upon newer, more-effective products for its success. Our report shows how technologies that increase clinical effectiveness, safety and ease of use will be crucial therapeutically and commercially, benefiting healthcare stakeholders in breast cancer treatment.
Detailed analysis of the breast cancer disorders industry and market
Breast Cancer Drugs: World Market Prospects 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of the R&D pipeline and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 40 tables and 30 figures included, as well as three full interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy Breast Cancer Drugs: World Market Prospects 2010-2025
This report gives you the following benefits in particular:
The breast cancer treatments market generated pharmaceutical revenues of over $11bn worldwide in 2009. The incidence and prevalence of breast cancer have been rising worldwide, in line with ageing populations, lifestyle/environmental factors and improvements in diagnosis. Expanding patient populations worldwide offer significant commercial and therapeutic opportunities, which our new report forecasts and discusses. Governments and other healthcare providers are investing in health education, diagnosis and treatments for this serious - but controllable - disorder.
As Breast Cancer Drugs: World Market Prospects 2010-2025 shows, breast cancer treatment is prominent in the healthcare sector. Which segments of the breast cancer market will grow fastest in years to come? How will the industry cope with patent expiry? What are the therapeutic and commercial trends to watch? How will national markets perform from 2010 to 2025? What will happen to the current leading products and drug classes? Our new report covers those and other questions, providing the information that you need.
We predict that the global market for breast cancer drugs will expand from 2010 onwards, driven by significant prevalence of the disease in developed and developing countries. National markets for those products will expand at different rates, as will different treatment forms. The market will depend upon newer, more-effective products for its success. Our report shows how technologies that increase clinical effectiveness, safety and ease of use will be crucial therapeutically and commercially, benefiting healthcare stakeholders in breast cancer treatment.
Detailed analysis of the breast cancer disorders industry and market
Breast Cancer Drugs: World Market Prospects 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of the R&D pipeline and analyses of commercial drivers and restraints, including a SWOT analysis. There are over 40 tables and 30 figures included, as well as three full interviews with experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.
Why you should buy Breast Cancer Drugs: World Market Prospects 2010-2025
This report gives you the following benefits in particular:
- You will receive a comprehensive analysis of the prospects for breast cancer drugs from 2010 to 2025, including predicted revenues, growth rates and other data for leading products
- You will receive an overall sales forecast for that market area from 2010 to 2025, as well as that for main drug classes, with comprehensive discussions and other supporting information
- You will find out where the market is heading - technologically and commercially - from 2010 onwards
- You will receive sales forecasts and other analysis for the leading national markets from 2010 to 2025 (US, Japan, France, Germany, UK, Spain, Italy, China and India)
- You will identify R&D pipeline developments and up-and-coming products
- You will discover the drivers, restraints, competition and opportunities influencing the breast cancer drug sector
- You will investigate under-met needs in that sector, with therapeutic requirements and commercial opportunities discussed
- You will discover expert views from our survey, including full interview transcripts.
1. EXECUTIVE SUMMARY
1.1 Breast Cancer Market Review
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outline
1.4 Research & Analysis Methods
2. INTRODUCTION TO BREAST CANCER
2.1 What is Breast Cancer?
2.2 Types of Breast Cancer
2.2.1 Pathology
2.2.2 Tumour Grade
2.2.3 Tumour Markers
2.2.4 The Staging System
2.3 Symptoms and Diagnosis
2.4 Risk Factors for Breast Cancer
2.5 Epidemiology of Breast Cancer
2.5.1 How Common is Breast Cancer?
2.5.2 How Does Geography Affect Breast Cancer Rates?
2.5.3 Is Incidence Rising?
3. TREATMENTS FOR BREAST CANCER, 2010
3.1 Chemotherapies
3.1.1 Anthracyclines
3.1.2 Drugs that Interfere with Microtubules
3.1.3 Anti-metabolites
3.1.4 Alkylating Agents (Cross-linkers)
3.1.5 Common Chemotherapy Combinations
3.2 Hormone Therapies
3.3 Targeted Therapies
3.4 Treatment Protocol
4. THE GLOBAL BREAST CANCER MARKET, 2009-2025
4.1 The Global Oncology Market
4.2 The Oncology Market by Therapy Type
4.3 The Breast Cancer Market
4.4 Global Breast Cancer Market Forecast
4.5 Targeted Therapy Submarket Forecast
4.6 Hormone Therapy Submarket Forecast
4.7 Cytotoxic Chemotherapies Submarket Forecast
5. LEADING BREAST CANCER DRUGS – GLOBAL MARKET PROSPECTS FROM 2010
5.1 Herceptin (trastuzumab, Roche)
5.1.1 Forecast and Analysis
5.2 Tykerb/Tyverb (lapatinib, GlaxoSmithKline)
5.2.1 Forecast and Analysis
5.3 Avastin (bevacizumab, Roche)
5.3.1 Forecast and Analysis
5.4 Nolvadex (tamoxifen, AstraZeneca)
5.4.1 Forecast and Analysis
5.5 Faslodex (fulvestrant, AstraZeneca)
5.5.1 Forecast and Analysis
5.6 Fareston (toremifene, Orion, GTx)
5.6.1 Forecast and Analysis
5.7 Arimidex (anastrazole, AstraZeneca)
5.7.1 Forecast and Analysis
5.8 Femara (letrozole, Novartis)
5.8.1 Forecast and Analysis
5.9 Aromasin (exemestane, Pfizer)
5.9.1 Forecast and Analysis
5.10 Zoladex (goserelin, AstraZeneca)
5.10.1 Forecast and Analysis
5.11 Taxol (paclitaxel, Bristol-Myers Squibb)
5.11.1 Forecast and Analysis
5.12 Abraxane (paclitaxel, Abraxis)
5.12.1 Forecast and Analysis
5.13 Taxotere (docetaxel, sanofi-aventis)
5.13.1 Forecast and Analysis
5.14 Ixempra (ixabipilone, Bristol-Myers Squibb)
5.14.1 Forecast and Analysis
5.15 Navelbine (vinorelbine, Pierre Fabre, GlaxoSmithKline, Baxter International)
5.15.1 Forecast and Analysis
5.16 Xeloda (capecitabine, Roche)
5.16.1 Forecast and Analysis
5.17 Gemzar (gemcitabine, Eli Lilly)
5.17.1 Forecast and Analysis
6. PROMINENT COMPANIES IN THE BREAST CANCER SECTOR
6.1 AstraZeneca
6.2 Roche
6.3 Bristol-Myers Squibb
6.4 Sanofi-Aventis
6.5 Abraxis BioScience
6.6 Hologic Inc.
6.7 Myriad Genetics
7. PROMINENT R&D PIPELINE AGENTS IN THE BREAST CANCER SECTOR, 2010
7.1 PARP Inhibitors
7.2 HER2/erbB
7.2.1 I-SPY2 TRIAL
7.3 Angiogenesis
7.4 Apoptosis
7.5 EGFR
7.6 Microtubules
7.7 Other Tyrosine Kinase
7.8 MUC-1
8. GEOGRAPHICAL BREAKDOWN OF THE BREAST CANCER MARKET, 2010-2025
8.1 Leading National Breast Cancer Markets in 2009
8.2 Leading National Market Forecasts, 2010-2025
8.3 The US: Breast Cancer Drug Market
8.4 Japan: Breast Cancer Drug Market
8.5 Europe: Breast Cancer Drug Markets
8.6 China: Breast Cancer Drug Market
8.7 India: Breast Cancer Drug Market
9. FACTORS AFFECTING THE BREAST CANCER DRUG MARKET, 2010-2025
9.1 Drivers of the Market
9.1.1 High Profile of the Disease
9.1.2 Number of Cases: Screening, Westernisation of Developing Nations, Growing Populations
9.1.3 The Price of Drugs
9.1.4 Drug Development
9.1.5 Live Licensing
9.1.6 The Cost of Non-Pharmacological Treatments
9.1.7 Treatment v Cure
9.1.8 Better Understanding of Breast Cancer Physiology
9.1.9 Personalised Medicine
9.1.10 Drug Delivery Systems
9.2 Restraints
9.2.1 The Cost-Effectiveness Debate
9.2.2 Healthcare Budgets
9.2.3 Efficacy, Toxicity and Alternative Treatments
9.2.4 The Patent Cliff
9.3 Unmet Needs in Treatment of Breast Cancer
9.3.1 Tolerable Drugs
9.3.2 More-Convenient Drugs
9.3.3 Tumour Resistance Must be Overcome
9.3.4 Greater Use of Pharmacogenomics
9.3.5 Rigorous Endpoints in Clinical Trials
9.3.6 The Screening Debate
9.3.7 Access to Novel Therapies in the Developing World
10. INTERVIEWS WITH EXPERTS
10.1 David A. Flockhart, PhD, MD
10.1.1 The Importance of Pharmacogenomics in Treating Breast Cancer
10.1.2 Major Breakthroughs
10.1.3 Personalised Medicine
10.1.4 Drivers
10.1.5 Restraints
10.1.6 Ethical Issues
10.1.7 Pre-emptive Treatment
10.2 Janice M. Reichert, PhD
10.2.1 Challenges and Opportunities for Monoclonal Antibody Cancer Therapeutics
10.2.2 Future Developments and Pipelines
10.2.3 The Effect of Biosimilars
10.3 David Blakey, PhD
10.3.1 The Future of Humanised and Fully-Human Antibodies
10.3.2 Therapeutic Antibody Fragments Versus Full-Length IgGs
10.3.3 Leading Opportunities in Monoclonal Antibody Cancer Therapeutics
11. CONCLUSIONS
11.1 The Breast Cancer Market is Strong and Expected to Grow from 2010
11.2 Leading Treatments for Breast Cancer
11.3 Will the R&D Pipeline Offset the Effects of Patent Expiry?
11.4 The US is the Most Important Breast Cancer Market, but China’s Growth is Faster
11.5 Personalised Medicine is the Future of Breast Cancer Treatment?
11.6 Unmet Needs in the Breast Cancer Market
11.7 Concluding Remarks
1.1 Breast Cancer Market Review
1.2 Aims, Scope and Format of the Report
1.3 Chapter Outline
1.4 Research & Analysis Methods
2. INTRODUCTION TO BREAST CANCER
2.1 What is Breast Cancer?
2.2 Types of Breast Cancer
2.2.1 Pathology
2.2.2 Tumour Grade
2.2.3 Tumour Markers
2.2.4 The Staging System
2.3 Symptoms and Diagnosis
2.4 Risk Factors for Breast Cancer
2.5 Epidemiology of Breast Cancer
2.5.1 How Common is Breast Cancer?
2.5.2 How Does Geography Affect Breast Cancer Rates?
2.5.3 Is Incidence Rising?
3. TREATMENTS FOR BREAST CANCER, 2010
3.1 Chemotherapies
3.1.1 Anthracyclines
3.1.2 Drugs that Interfere with Microtubules
3.1.3 Anti-metabolites
3.1.4 Alkylating Agents (Cross-linkers)
3.1.5 Common Chemotherapy Combinations
3.2 Hormone Therapies
3.3 Targeted Therapies
3.4 Treatment Protocol
4. THE GLOBAL BREAST CANCER MARKET, 2009-2025
4.1 The Global Oncology Market
4.2 The Oncology Market by Therapy Type
4.3 The Breast Cancer Market
4.4 Global Breast Cancer Market Forecast
4.5 Targeted Therapy Submarket Forecast
4.6 Hormone Therapy Submarket Forecast
4.7 Cytotoxic Chemotherapies Submarket Forecast
5. LEADING BREAST CANCER DRUGS – GLOBAL MARKET PROSPECTS FROM 2010
5.1 Herceptin (trastuzumab, Roche)
5.1.1 Forecast and Analysis
5.2 Tykerb/Tyverb (lapatinib, GlaxoSmithKline)
5.2.1 Forecast and Analysis
5.3 Avastin (bevacizumab, Roche)
5.3.1 Forecast and Analysis
5.4 Nolvadex (tamoxifen, AstraZeneca)
5.4.1 Forecast and Analysis
5.5 Faslodex (fulvestrant, AstraZeneca)
5.5.1 Forecast and Analysis
5.6 Fareston (toremifene, Orion, GTx)
5.6.1 Forecast and Analysis
5.7 Arimidex (anastrazole, AstraZeneca)
5.7.1 Forecast and Analysis
5.8 Femara (letrozole, Novartis)
5.8.1 Forecast and Analysis
5.9 Aromasin (exemestane, Pfizer)
5.9.1 Forecast and Analysis
5.10 Zoladex (goserelin, AstraZeneca)
5.10.1 Forecast and Analysis
5.11 Taxol (paclitaxel, Bristol-Myers Squibb)
5.11.1 Forecast and Analysis
5.12 Abraxane (paclitaxel, Abraxis)
5.12.1 Forecast and Analysis
5.13 Taxotere (docetaxel, sanofi-aventis)
5.13.1 Forecast and Analysis
5.14 Ixempra (ixabipilone, Bristol-Myers Squibb)
5.14.1 Forecast and Analysis
5.15 Navelbine (vinorelbine, Pierre Fabre, GlaxoSmithKline, Baxter International)
5.15.1 Forecast and Analysis
5.16 Xeloda (capecitabine, Roche)
5.16.1 Forecast and Analysis
5.17 Gemzar (gemcitabine, Eli Lilly)
5.17.1 Forecast and Analysis
6. PROMINENT COMPANIES IN THE BREAST CANCER SECTOR
6.1 AstraZeneca
6.2 Roche
6.3 Bristol-Myers Squibb
6.4 Sanofi-Aventis
6.5 Abraxis BioScience
6.6 Hologic Inc.
6.7 Myriad Genetics
7. PROMINENT R&D PIPELINE AGENTS IN THE BREAST CANCER SECTOR, 2010
7.1 PARP Inhibitors
7.2 HER2/erbB
7.2.1 I-SPY2 TRIAL
7.3 Angiogenesis
7.4 Apoptosis
7.5 EGFR
7.6 Microtubules
7.7 Other Tyrosine Kinase
7.8 MUC-1
8. GEOGRAPHICAL BREAKDOWN OF THE BREAST CANCER MARKET, 2010-2025
8.1 Leading National Breast Cancer Markets in 2009
8.2 Leading National Market Forecasts, 2010-2025
8.3 The US: Breast Cancer Drug Market
8.4 Japan: Breast Cancer Drug Market
8.5 Europe: Breast Cancer Drug Markets
8.6 China: Breast Cancer Drug Market
8.7 India: Breast Cancer Drug Market
9. FACTORS AFFECTING THE BREAST CANCER DRUG MARKET, 2010-2025
9.1 Drivers of the Market
9.1.1 High Profile of the Disease
9.1.2 Number of Cases: Screening, Westernisation of Developing Nations, Growing Populations
9.1.3 The Price of Drugs
9.1.4 Drug Development
9.1.5 Live Licensing
9.1.6 The Cost of Non-Pharmacological Treatments
9.1.7 Treatment v Cure
9.1.8 Better Understanding of Breast Cancer Physiology
9.1.9 Personalised Medicine
9.1.10 Drug Delivery Systems
9.2 Restraints
9.2.1 The Cost-Effectiveness Debate
9.2.2 Healthcare Budgets
9.2.3 Efficacy, Toxicity and Alternative Treatments
9.2.4 The Patent Cliff
9.3 Unmet Needs in Treatment of Breast Cancer
9.3.1 Tolerable Drugs
9.3.2 More-Convenient Drugs
9.3.3 Tumour Resistance Must be Overcome
9.3.4 Greater Use of Pharmacogenomics
9.3.5 Rigorous Endpoints in Clinical Trials
9.3.6 The Screening Debate
9.3.7 Access to Novel Therapies in the Developing World
10. INTERVIEWS WITH EXPERTS
10.1 David A. Flockhart, PhD, MD
10.1.1 The Importance of Pharmacogenomics in Treating Breast Cancer
10.1.2 Major Breakthroughs
10.1.3 Personalised Medicine
10.1.4 Drivers
10.1.5 Restraints
10.1.6 Ethical Issues
10.1.7 Pre-emptive Treatment
10.2 Janice M. Reichert, PhD
10.2.1 Challenges and Opportunities for Monoclonal Antibody Cancer Therapeutics
10.2.2 Future Developments and Pipelines
10.2.3 The Effect of Biosimilars
10.3 David Blakey, PhD
10.3.1 The Future of Humanised and Fully-Human Antibodies
10.3.2 Therapeutic Antibody Fragments Versus Full-Length IgGs
10.3.3 Leading Opportunities in Monoclonal Antibody Cancer Therapeutics
11. CONCLUSIONS
11.1 The Breast Cancer Market is Strong and Expected to Grow from 2010
11.2 Leading Treatments for Breast Cancer
11.3 Will the R&D Pipeline Offset the Effects of Patent Expiry?
11.4 The US is the Most Important Breast Cancer Market, but China’s Growth is Faster
11.5 Personalised Medicine is the Future of Breast Cancer Treatment?
11.6 Unmet Needs in the Breast Cancer Market
11.7 Concluding Remarks
LIST OF TABLES
Table 2.1 Types of Breast Cancer
Table 2.2 Bloom-Richardson Grading System
Table 2.3 TNM Staging System for Breast Cancer
Table 2.4 Cancers by Incidence, 2009
Table 2.5 Female Cancers by Incidence, 2009
Table 2.6 Female Cancers by Mortality, 2009
Table 2.7 Age-Standardised Mortality and Incidence of Breast Cancer in Developed and Developing Countries, 2002
Table 2.8 Survival Rates for Selected Cancers, 2010
Table 2.9 US Breast Cancer Incidence Rates, 1975-2006
Table 2.10 Breast Cancer Incidence Rates in Nordic Countries, 1998-2005
Table 3.1 Chemotherapy Combinations for Breast Cancer
Table 4.1 Global Pharmaceutical Sales by Disease Area, 2009
Table 4.2 Oncology Market by Therapy Type, 2009
Table 4.3 Breast Cancer Market by Therapy Type, 2009
Table 4.4 Breast Cancer Market Forecast: Overall and by Therapy Type, 2010-2025
Table 5.1 Herceptin Sales Forecast, 2010-2025
Table 5.2 Tykerb Sales Forecast, 2010-2025
Table 5.3 Avastin Sales Forecast, 2010-2025
Table 5.4 Nolvadex Sales Forecast, 2010-2025
Table 5.5 Faslodex Sales Forecast, 2010-2025
Table 5.6 Fareston Sales Forecast, 2010-2025
Table 5.7 Arimidex Sales Forecast, 2010-2025
Table 5.8 Femara Sales Forecast, 2010-2025
Table 5.9 Aromasin Sales Forecast, 2010-2025
Table 5.10 Zoladex Sales Forecast, 2010-2025
Table 5.11 Taxol Sales Forecast, 2010-2025
Table 5.12 Abraxane Sales Forecast, 2010-2025
Table 5.13 Taxotere Sales Forecast, 2010-2025
Table 5.14 Ixempra Sales Forecast, 2010-2025
Table 5.15 Navelbine Sales Forecast, 2010-2025
Table 5.16 Xeloda Sales Forecast, 2010-2025
Table 5.17 Gemzar Sales Forecast, 2010-2025
Table 5.18 Leading Breast Cancer Drugs: Sales Forecasts, 2010-2025
Table 6.1 AstraZeneca Breast Cancer Portfolio, 2009
Table 6.2 Roche Breast Cancer Portfolio, 2009
Table 6.3 Bristol-Myers Squibb Breast Cancer Portfolio, 2009
Table 6.4 Sanofi-Aventis Breast Cancer Portfolio, 2009
Table 6.5 Abraxane Breast Cancer Portfolio, 2009
Table 7.1 Promising Pipeline Agents for Breast Cancer, 2010
Table 8.1 Leading National Breast Cancer Markets: Sales and Market Shares, 2009
Table 8.2 Leading National Breast Cancer Markets: Sales Forecasts, 2010-2025
Table 8.3 US Breast Cancer Incidence, 2001-2006
Table 8.4 Breast Cancer Incidence by Country, 2002
Table 8.5 Healthcare Spending in Europe, 2009
Table 9.1 SWOT Analysis of the Breast Cancer Drug Market, 2010-2025
Table 9.2 GDP Forecasts for BRICT Countries and US, 2010-2025
Table 2.1 Types of Breast Cancer
Table 2.2 Bloom-Richardson Grading System
Table 2.3 TNM Staging System for Breast Cancer
Table 2.4 Cancers by Incidence, 2009
Table 2.5 Female Cancers by Incidence, 2009
Table 2.6 Female Cancers by Mortality, 2009
Table 2.7 Age-Standardised Mortality and Incidence of Breast Cancer in Developed and Developing Countries, 2002
Table 2.8 Survival Rates for Selected Cancers, 2010
Table 2.9 US Breast Cancer Incidence Rates, 1975-2006
Table 2.10 Breast Cancer Incidence Rates in Nordic Countries, 1998-2005
Table 3.1 Chemotherapy Combinations for Breast Cancer
Table 4.1 Global Pharmaceutical Sales by Disease Area, 2009
Table 4.2 Oncology Market by Therapy Type, 2009
Table 4.3 Breast Cancer Market by Therapy Type, 2009
Table 4.4 Breast Cancer Market Forecast: Overall and by Therapy Type, 2010-2025
Table 5.1 Herceptin Sales Forecast, 2010-2025
Table 5.2 Tykerb Sales Forecast, 2010-2025
Table 5.3 Avastin Sales Forecast, 2010-2025
Table 5.4 Nolvadex Sales Forecast, 2010-2025
Table 5.5 Faslodex Sales Forecast, 2010-2025
Table 5.6 Fareston Sales Forecast, 2010-2025
Table 5.7 Arimidex Sales Forecast, 2010-2025
Table 5.8 Femara Sales Forecast, 2010-2025
Table 5.9 Aromasin Sales Forecast, 2010-2025
Table 5.10 Zoladex Sales Forecast, 2010-2025
Table 5.11 Taxol Sales Forecast, 2010-2025
Table 5.12 Abraxane Sales Forecast, 2010-2025
Table 5.13 Taxotere Sales Forecast, 2010-2025
Table 5.14 Ixempra Sales Forecast, 2010-2025
Table 5.15 Navelbine Sales Forecast, 2010-2025
Table 5.16 Xeloda Sales Forecast, 2010-2025
Table 5.17 Gemzar Sales Forecast, 2010-2025
Table 5.18 Leading Breast Cancer Drugs: Sales Forecasts, 2010-2025
Table 6.1 AstraZeneca Breast Cancer Portfolio, 2009
Table 6.2 Roche Breast Cancer Portfolio, 2009
Table 6.3 Bristol-Myers Squibb Breast Cancer Portfolio, 2009
Table 6.4 Sanofi-Aventis Breast Cancer Portfolio, 2009
Table 6.5 Abraxane Breast Cancer Portfolio, 2009
Table 7.1 Promising Pipeline Agents for Breast Cancer, 2010
Table 8.1 Leading National Breast Cancer Markets: Sales and Market Shares, 2009
Table 8.2 Leading National Breast Cancer Markets: Sales Forecasts, 2010-2025
Table 8.3 US Breast Cancer Incidence, 2001-2006
Table 8.4 Breast Cancer Incidence by Country, 2002
Table 8.5 Healthcare Spending in Europe, 2009
Table 9.1 SWOT Analysis of the Breast Cancer Drug Market, 2010-2025
Table 9.2 GDP Forecasts for BRICT Countries and US, 2010-2025
LIST OF FIGURES
Figure 2.1 Top Ten Cancers by Incidence, 2009
Figure 2.2 Top Ten Female Cancers by Incidence, 2009
Figure 2.3 Top Ten Female Cancers by Mortality, 2009
Figure 2.4 Age-Standardised Mortality and Incidence of Breast Cancer in Developed and Developing Countries, 2002
Figure 2.5 Survival Rates for Selected Cancers, 2010
Figure 2.6 US Breast Cancer Incidence Rates, 1975-2006
Figure 2.7 Breast Cancer Incidence Rates in Nordic Countries, 1975-2006
Figure 4.1 Oncology Market by Therapy Type, 2009
Figure 4.2 Breast Cancer Market by Therapy Type, 2009
Figure 4.3 Global Breast Cancer Market Sales Forecast, 2010-2025
Figure 4.4 Breast Cancer Targeted Therapies Submarket Sales Forecast, 2010-2025
Figure 4.5 Breast Cancer Hormone Therapies Submarket Sales Forecast, 2010-2025
Figure 4.6 Breast Cancer Chemotherapy Submarket Sales Forecast, 2010-2025
Figure 4.7 Global Breast Cancer Market: Sales Forecast by Therapy Type, 2010-2025
Figure 5.1 Herceptin Sales Forecast, 2010-2025
Figure 5.2 Tykerb Sales Forecast, 2010-2025
Figure 5.3 Avastin Sales Forecast, 2010-2025
Figure 5.4 Nolvadex Sales Forecast, 2010-2025
Figure 5.5 Faslodex Sales Forecast, 2010-2025
Figure 5.6 Fareston Sales Forecast, 2010-2025
Figure 5.7 Arimidex Sales Forecast, 2010-2025
Figure 5.8 Femara Sales Forecast, 2010-2025
Figure 5.9 Aromasin Sales Forecast, 2010-2025
Figure 5.10 Zoladex Sales Forecast, 2010-2025
Figure 5.11 Taxol Sales Forecast, 2010-2025
Figure 5.12 Abraxane Sales Forecast, 2010-2025
Figure 5.13 Taxotere Sales Forecast, 2010-2025
Figure 5.14 Ixempra Sales Forecast, 2010-2025
Figure 5.15 Navelbine Sales Forecast, 2010-2025
Figure 5.16 Xeloda Sales Forecast, 2010-2025
Figure 5.17 Gemzar Sales Forecast, 2010-2025
Figure 8.1 Leading National Breast Cancer Markets (Upper Tier): Sales Forecasts, 2010-2025
Figure 8.2 Leading National Breast Cancer Markets (Lower Tier): Sales Forecasts, 2010-2025
COMPANIES LISTED
Abbott Laboratories
Abraxis Bioscience Inc.
ADVENTRX Pharmaceuticals
Agence Nationale de Valorisation de la Recherche (ANVAR)
American Civil Liberties Union (ACLU)
American Society of Clinical Oncology
Amgen
Apotex
Apthera
ASTA Medica Oncology
AstraZeneca
Baxter International
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
British Medical Journal
Cancer Research UK
Centre National de la Recherche Scientifique (CNRS)
Cephalon
Chugai Pharmaceutical Co.
Consortium on Breast Cancer Pharmacogenomics (COBRA)
CytImmune Sciences
Eisai
Eli Lilly
Endocyte
European Medicines Agency (EMEA)
Florida State University
Food and Drug Administration (FDA)
Genentech
GlaxoSmithKline
GTx
Hologic
Hospira
ICI Pharmaceuticals
Indiana University School of Medicine
International Monetary Fund (IMF)
Ipsen
Johnson & Johnson
Journal of Medical Screening
KuDOS Pharmaceuticals
Kyowa Hakko Kirin
Laboratoires Pierre Fabre
mAbs
Medicare
Merck & Co.
Merck KGaA
Merck Serono
Myriad Genetics
National Cancer Institute (NCI, US)
National Health Service (NHS, UK)
National Institute for Clinical Excellence (NICE, UK)
Novartis
Oncothyreon
Orion Corporation
Pfizer
Piramed
Prima BioMed
Regeneron
Roche
sanofi-aventis
Serono
STADA Arzneimittel AG
Teva Pharmaceutical Industries
The Mayo Clinic
Tufts University
US Preventative Services Task Force
World Bank
World Health Organisation (WHO)
Wyeth (now part of Pfizer)
Figure 2.1 Top Ten Cancers by Incidence, 2009
Figure 2.2 Top Ten Female Cancers by Incidence, 2009
Figure 2.3 Top Ten Female Cancers by Mortality, 2009
Figure 2.4 Age-Standardised Mortality and Incidence of Breast Cancer in Developed and Developing Countries, 2002
Figure 2.5 Survival Rates for Selected Cancers, 2010
Figure 2.6 US Breast Cancer Incidence Rates, 1975-2006
Figure 2.7 Breast Cancer Incidence Rates in Nordic Countries, 1975-2006
Figure 4.1 Oncology Market by Therapy Type, 2009
Figure 4.2 Breast Cancer Market by Therapy Type, 2009
Figure 4.3 Global Breast Cancer Market Sales Forecast, 2010-2025
Figure 4.4 Breast Cancer Targeted Therapies Submarket Sales Forecast, 2010-2025
Figure 4.5 Breast Cancer Hormone Therapies Submarket Sales Forecast, 2010-2025
Figure 4.6 Breast Cancer Chemotherapy Submarket Sales Forecast, 2010-2025
Figure 4.7 Global Breast Cancer Market: Sales Forecast by Therapy Type, 2010-2025
Figure 5.1 Herceptin Sales Forecast, 2010-2025
Figure 5.2 Tykerb Sales Forecast, 2010-2025
Figure 5.3 Avastin Sales Forecast, 2010-2025
Figure 5.4 Nolvadex Sales Forecast, 2010-2025
Figure 5.5 Faslodex Sales Forecast, 2010-2025
Figure 5.6 Fareston Sales Forecast, 2010-2025
Figure 5.7 Arimidex Sales Forecast, 2010-2025
Figure 5.8 Femara Sales Forecast, 2010-2025
Figure 5.9 Aromasin Sales Forecast, 2010-2025
Figure 5.10 Zoladex Sales Forecast, 2010-2025
Figure 5.11 Taxol Sales Forecast, 2010-2025
Figure 5.12 Abraxane Sales Forecast, 2010-2025
Figure 5.13 Taxotere Sales Forecast, 2010-2025
Figure 5.14 Ixempra Sales Forecast, 2010-2025
Figure 5.15 Navelbine Sales Forecast, 2010-2025
Figure 5.16 Xeloda Sales Forecast, 2010-2025
Figure 5.17 Gemzar Sales Forecast, 2010-2025
Figure 8.1 Leading National Breast Cancer Markets (Upper Tier): Sales Forecasts, 2010-2025
Figure 8.2 Leading National Breast Cancer Markets (Lower Tier): Sales Forecasts, 2010-2025
COMPANIES LISTED
Abbott Laboratories
Abraxis Bioscience Inc.
ADVENTRX Pharmaceuticals
Agence Nationale de Valorisation de la Recherche (ANVAR)
American Civil Liberties Union (ACLU)
American Society of Clinical Oncology
Amgen
Apotex
Apthera
ASTA Medica Oncology
AstraZeneca
Baxter International
Bayer
Boehringer Ingelheim
Bristol-Myers Squibb
British Medical Journal
Cancer Research UK
Centre National de la Recherche Scientifique (CNRS)
Cephalon
Chugai Pharmaceutical Co.
Consortium on Breast Cancer Pharmacogenomics (COBRA)
CytImmune Sciences
Eisai
Eli Lilly
Endocyte
European Medicines Agency (EMEA)
Florida State University
Food and Drug Administration (FDA)
Genentech
GlaxoSmithKline
GTx
Hologic
Hospira
ICI Pharmaceuticals
Indiana University School of Medicine
International Monetary Fund (IMF)
Ipsen
Johnson & Johnson
Journal of Medical Screening
KuDOS Pharmaceuticals
Kyowa Hakko Kirin
Laboratoires Pierre Fabre
mAbs
Medicare
Merck & Co.
Merck KGaA
Merck Serono
Myriad Genetics
National Cancer Institute (NCI, US)
National Health Service (NHS, UK)
National Institute for Clinical Excellence (NICE, UK)
Novartis
Oncothyreon
Orion Corporation
Pfizer
Piramed
Prima BioMed
Regeneron
Roche
sanofi-aventis
Serono
STADA Arzneimittel AG
Teva Pharmaceutical Industries
The Mayo Clinic
Tufts University
US Preventative Services Task Force
World Bank
World Health Organisation (WHO)
Wyeth (now part of Pfizer)
